Results of first Phase III abiraterone acetate trial to be presented at ESMO
Posted Oct 04 2010 12:00am
The “New” Prostate Cancer InfoLink has learned that the results of the Phase III clinical trial of abiraterone acetate + prednisone in patients who progressed after treatment with docetaxel-based chemotherapy will be presented on October 11 at the annual meeting of the European Society for Medical Oncology (ESMO) in Milan, Italy.
As previously reported , we know that the results of this trial are positive. This is confirmed by the title of the actual presentation: “Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study.” The actual presentation will be given by Dr. Johann de Bono one of the principal investigators for this trial.
The “New” Prostate Cancer InfoLink has learned that the results of the Phase III clinical trial of abiraterone acetate + prednisone in patients who progressed after treatment with docetaxel-based chemotherapy will be presented on October 11 at the annual meeting of the European Society for Medical Oncology (ESMO) in Milan, Italy.
As previously reported , we know that the results of this trial are positive. This is confirmed by the title of the actual presentation: “Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study.” The actual presentation will be given by Dr. Johann de Bono one of the principal investigators for this trial.